Armour Thyroid vs Cytomel (Liothyronine): Cost and Access Head-to-Head

What Each Drug Actually Contains

Armour Thyroid is a natural desiccated thyroid (NDT) product derived from porcine thyroid glands. Each grain (60 mg) delivers approximately 38 mcg of levothyroxine (T4) and 9 mcg of liothyronine (T3). That fixed T4:T3 ratio of roughly 4.2:1 does not match the human thyroid's secretion ratio of approximately 13:1, which means patients on Armour Thyroid absorb proportionally more T3 than their own gland would produce.

Cytomel, by contrast, is pure synthetic liothyronine sodium. It contains no T4. This distinction matters clinically because T3 has a short half-life of roughly 1 to 2 days compared to T4's 6- to 7-day half-life, producing more pronounced serum T3 peaks after dosing. Clinicians who prescribe Cytomel or generic liothyronine sometimes split the daily dose into two administrations to reduce these fluctuations, a strategy supported by pharmacokinetic data published in Thyroid.

One pill does not replace the other milligram-for-milligram. A patient on Armour Thyroid 60 mg is receiving both hormones simultaneously, while a patient on Cytomel 25 mcg is receiving T3 alone and will need separate levothyroxine if T4 replacement is also required.

Retail Cost Comparison

Generic liothyronine is one of the least expensive thyroid medications on the U.S. market. A 30-day supply of liothyronine 25 mcg typically costs between $10 and $30 at major chain pharmacies without insurance, often falling below $15 with discount programs. Brand-name Cytomel (Pfizer) costs considerably more, often $100 or above for a 30-day supply, but very few prescriptions are filled as brand Cytomel because generics are AB-rated and widely available.

Armour Thyroid pricing sits higher than generic liothyronine but lower than brand Cytomel. A 30-day supply of Armour Thyroid 60 mg (1 grain) ranges from $30 to $90 depending on the pharmacy, with independent pharmacies sometimes offering lower cash prices than chains. Armour Thyroid has no AB-rated generic equivalent. NP Thyroid and WP Thyroid are alternative NDT products, not generic substitutions, and pharmacists cannot automatically interchange them without prescriber authorization.

For patients who need both T4 and T3 replacement, the total cost picture shifts. Generic levothyroxine (25 to 200 mcg) costs $4 to $15 per month, so combining generic levothyroxine plus generic liothyronine typically runs $14 to $45 per month. That combination may be cheaper than Armour Thyroid while giving the prescriber independent dose control over each hormone.

Insurance Coverage and Formulary Placement

Insurance formularies treat these two medications differently, and the gap affects out-of-pocket costs more than retail pricing does. Generic liothyronine appears on Tier 1 (preferred generic) of most commercial and Medicare Part D plans. Copays typically run $0 to $15 per month. Prior authorization is rarely required for liothyronine prescribed by an endocrinologist, though some plans require a documented trial of levothyroxine monotherapy first.

Armour Thyroid occupies Tier 2 or Tier 3 on many formularies. Some insurers classify it as a "non-preferred brand" because no generic NDT with formal AB-rating exists. Copays range from $25 to $60, and step therapy requirements are common. The American Thyroid Association's 2014 guidelines favor levothyroxine monotherapy as the standard of care, and payers cite these guidelines when restricting NDT coverage.

Medicaid coverage varies by state. As of 2025, at least 12 state Medicaid programs cover Armour Thyroid only with prior authorization, while generic liothyronine is covered in all 50 states at preferred tier. Patients on Medicaid or high-deductible commercial plans often find generic liothyronine the more accessible option by a wide margin.

Pharmacy Availability and Supply Chain

Generic liothyronine is manufactured by multiple companies, including Mylan (Viatris), Lannett, and Sigmapharm. This multi-source supply keeps availability stable. Stock-outs are infrequent and usually resolve within days as pharmacies source from alternative distributors.

Armour Thyroid has a single manufacturer: AbbVie (through its Allergan acquisition). Single-source manufacturing creates vulnerability. Armour Thyroid experienced notable shortages in 2009 and 2012, forcing thousands of patients to switch medications abruptly. A shorter disruption occurred during early 2020 supply chain instability. These shortages prompted the ATA to issue guidance on transitioning NDT patients to synthetic alternatives during supply interruptions.

Compounding pharmacies offer a workaround during shortages. Compounded desiccated thyroid or custom T4/T3 combinations can be prepared, but compounded products lack the batch-to-batch potency standardization of FDA-approved tablets. The FDA has noted that compounded thyroid products do not undergo the same dissolution and bioavailability testing as manufactured tablets.

Clinical Evidence: Efficacy Signals

No randomized controlled trial has directly compared Armour Thyroid to Cytomel (liothyronine) head-to-head. The published evidence compares each drug against levothyroxine monotherapy, with the best data coming from two key trials.

Hoang et al. published a crossover study in the Journal of Clinical Endocrinology & Metabolism (2013) comparing desiccated thyroid extract (DTE) to levothyroxine in 70 hypothyroid patients over 16 weeks per treatment arm. TSH normalization rates were similar between groups. Patients on DTE lost an average of 1.5 kg more than those on levothyroxine (P = 0.02), and 48.6% preferred DTE versus 18.6% preferring levothyroxine. Serum T3 levels were higher in the DTE group.

The earlier Bunevicius et al. trial in the New England Journal of Medicine (1999) replaced 50 mcg of a patient's levothyroxine dose with 12.5 mcg of liothyronine in 33 patients over 5 weeks. The T4/T3 combination improved scores on 6 of 17 neuropsychological tests and several mood measures compared to T4 alone. This small, short trial generated widespread clinical interest in T3 supplementation but has not been consistently replicated at scale.

A 2006 meta-analysis of 11 RCTs comparing T4/T3 combination therapy to T4 monotherapy, published in the Journal of Clinical Endocrinology & Metabolism, found no consistent benefit of combination therapy on body weight, anxiety, depression, or quality of life. The analysis noted significant heterogeneity in T3 dosing protocols across trials.

"There is no consistently strong evidence that DTE or T3 combination therapy is superior to levothyroxine monotherapy for the majority of hypothyroid patients," states the ATA/AACE 2012 clinical practice guideline. The 2014 ATA guideline update maintained this position while acknowledging that a subgroup of patients may prefer and respond to T3-containing regimens.

Who Gets Prescribed Which Drug

Prescribing patterns differ by specialty and clinical context. Endocrinologists prescribe liothyronine more frequently than NDT products when adding T3 to a patient's regimen. A survey published in Thyroid (2019) found that 3.6% of endocrinologists reported prescribing desiccated thyroid, compared to 15.2% who prescribed liothyronine in some form.

Integrative and functional medicine practitioners prescribe Armour Thyroid at much higher rates. In these practice settings, NDT is sometimes framed as a "natural" alternative to synthetic hormones. The porcine origin and combined T4/T3 content appeal to patients who prefer animal-derived medications.

Specific clinical scenarios may favor one over the other:

• Persistent symptoms on levothyroxine monotherapy with normal TSH: Either drug may be trialed. Liothyronine allows dose-specific T3 titration without altering T4 dose.
• T3 suppression therapy for differentiated thyroid cancer: Synthetic liothyronine is standard for short-term TSH suppression before radioactive iodine therapy or Thyrogen-stimulated thyroglobulin testing. Armour Thyroid is not used in this context because its T4 content would delay T4 washout.
• Patient preference for combined T4/T3 in a single pill: Armour Thyroid simplifies the regimen to one medication. The tradeoff is fixed-ratio dosing without independent hormone titration.
• Cost-sensitive patients without insurance: Generic liothyronine wins on price. If T4 replacement is also needed, adding $4 generic levothyroxine still costs less than most Armour Thyroid fills.

How to Switch Between Armour Thyroid and Liothyronine

Switching from Armour Thyroid to liothyronine (or vice versa) is not a direct milligram-to-milligram conversion. The prescriber must account for the T4 component being added or removed. A patient on Armour Thyroid 60 mg who switches to synthetic hormones would need approximately 38 mcg of levothyroxine plus 9 mcg of liothyronine to match the hormone content, though clinical response may require dose adjustment.

The ATA recommends checking TSH, free T4, and free T3 six weeks after any thyroid medication change. During the transition period, patients should report symptoms of overreplacement (palpitations, tremor, insomnia, anxiety) or underreplacement (fatigue, weight gain, cold intolerance). Most transitions stabilize within one to two dose adjustments over 6 to 12 weeks.

"Patients switching from desiccated thyroid to levothyroxine, or vice versa, should be monitored with serum TSH at 6-week intervals until a stable dose is established," per the ATA 2014 hypothyroidism guidelines.

Abrupt switching without bridging is safe in most cases because both medications reach steady state within their respective half-lives. The exception is patients with cardiovascular disease, where gradual T3 dose titration is preferred to avoid cardiac stress from T3 peaks.

Practical Decision Framework

Choosing between these two drugs comes down to five variables: what hormones the patient needs replaced, whether independent dose titration matters, insurance coverage, supply reliability, and patient preference.

If a patient needs only T3 (for cancer suppression protocols, or as an add-on to existing levothyroxine), generic liothyronine is the clear choice. It is cheaper, more widely available, and allows precise T3 dosing.

If a patient wants both T4 and T3 in a single tablet and has adequate insurance coverage, Armour Thyroid offers convenience. The patient accepts a fixed hormone ratio and single-source supply risk in exchange for a simpler regimen.

For uninsured or underinsured patients, the combination of generic levothyroxine ($4 to $15/month) plus generic liothyronine ($10 to $30/month) provides the same two hormones at a combined cost that undercuts most Armour Thyroid fills while preserving the ability to titrate each hormone independently.

Patients filling either medication should confirm with their pharmacy that the same manufacturer's product is dispensed consistently, as switching between generic manufacturers can alter bioavailability enough to shift TSH by 10% to 20%, per FDA bioequivalence standards for narrow therapeutic index drugs.